Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 67Carcinoma, Non-Small-Cell Lung 45Lung Neoplasms 42Lymphoma 36Prostatic Neoplasms 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Ovarian Neoplasms 27Uterine Cervical Neoplasms 23Central Nervous System Neoplasms 22Neoplasm Metastasis 21Fallopian Tube Neoplasms 21Colorectal Neoplasms 21Leukemia 20Neuroblastoma 17Head and Neck Neoplasms 17Rectal Neoplasms 16Brain Neoplasms 16Adenocarcinoma of Lung 16Sarcoma 15Squamous Cell Carcinoma of Head and Neck 14Glioblastoma 14Colonic Neoplasms 14Burkitt Lymphoma 14Leukemia, Myeloid, Acute 13HIV Infections 13Urinary Bladder Neoplasms 12Lymphoma, Large B-Cell, Diffuse 12Multiple Myeloma 11Hodgkin Disease 11Astrocytoma 11

Interventions

merphos 2Methotrexate 2Dactinomycin 2Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Has results × Hydatidiform Mole × Clear all
NCT01535053 2022-08-12

Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia

GOG Foundation

Phase 3 Completed
57 enrolled 12 charts

Choriocarcinoma, Hydatidiform Mole

NCT00003702 2018-05-15

Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia

GOG Foundation

Phase 3 Completed
240 enrolled 9 charts

Hydatidiform Mole

Data powered by HemOnc (CC BY 4.0) Colophon âš¡